Arizona's Care1st Health Plan launches Pacify mobile app for mothers on Medicaid

Care1st Health Plan of Arizona announced its Pacify mobile application program for Medicaid members who are expecting mothers or mothers within a year of giving birth.

Pacify offers new mothers the ability to access a variety of professional 24/7 services through their smartphone. Members are able to communicate with certified professionals including lactation consultants and nutritionists through a live telehealth video conference. Mothers can also access information on breastfeeding and infant health issues such as colic, digestion and more.

"We understand how important these early years are to both mothers and their young children when instilling healthy habits that will affect a lifetime," said Scott Cummings, state president of Care1st. "This collaboration is exciting because it will aid us as we strive to promote the health and wellness of our members in a more interactive and modern way."

The app is also equipped with push notifications that pop-up routinely and contain health or safety tips for both mother and baby.

"The Pacify mobile app will provide immediate, cutting-edge support for new moms at the touch of a button," said George Brandes, co-founder and COO of Pacify Health. "Care1st members will now have an unprecedented level of access to care, with video-enabled consults available even in the middle of the night and on weekends when there aren't a lot of other options."

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.